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CLINICAL STUDIES IN THE INTENSIVE
CARE UNIT
ETHICAL AND LEGAL ASPECTS
Erwin Deutsch*
This article draws on international experience to explore the ethical and legal aspects of
perjorming clinical studies on patients in intensive care units. It discusses aspects Of consent
relevant to clinical studies in this medical environment, it considers the involvement Of ethical
committees, and the role and appropriate level of insurance cover.
I FACTUAL STARTING POINT
Clinical studies that are performed in the intensive care unit (ICU) take place on
patients, not probands. Two rules of the Revised Declaration of Helsinki by the World
Medical Assembly, as amended in Hong Kong in 1989, limit experimentation on patients.
The rules are:1
I. 10
When obtaining informed consent for the research project the doctor should be particularly
cautious if the subject is in a dependant relationship to him or her or may consent under
duress. In that case the informed consent should be obtained by a doctor who is not engaged
in the investigation, and who is completely independent of this official relationship.
* Professor of Law, University of Gottingen, Visiting Professor, Law Faculty, Victoria University of
Wellington.
1 The World Medical Association: Declaration of Helsinki: Recommendations guiding medical
doctors in biomedical research involving human subjects adopted by the 185th World Medical
Assembly as revised by the 29th World Medical Assembly (1975). Recent changes of the Revised
Declaration of Helsinki did not concern these two rules.
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n. 6
The doctor can combine medical research with professional care, the objective being the
acquisition of new medical knowledge, only to the extent that medical research is justified by
its potential diagnostic or therapeutic value for the patient.
A patient in hospital, especially one in the ICU, is dependent on the personnel employed
by the hospital and especially on the doctors. Therefore using a patient in a clinical study
necessitates employing another doctor to obtain the informed consent that has to be given by
the patient. Rule I. 10 of the Revised Declaration of Helsinki assumes that there is a bond
between the doctor who provides professional care and the patient. That bond should not
be used as a means of obtaining the informed consent.
Rule II. 6 of the Revised Declaration of Helsinki allows medical research to be combined
with professional care. This does not go without saying because using one's patient as an
experimental subject is not self-evident in research. There are limitations as well. The
medical research has to be justified by its potential diagnostic or therapeutic value for the
patient. This seems to disallow purely scientific research on a patient done by the doctor
who also provides professional care.
The abovestated rules apply to all patients under professional care but especially to
patients in the ICU. Here the bond between the doctor and the patient is a strong one and
the doctor's influence is even greater than in the normal ward or in the office of the
practitioner.
II RESEARCH ON PATIENTS UNABLE TO CONSENT
The Revised Declaration of Helsinki allows research in I. 11 on subjects unable to
consent.
In case of Iegal incompetence, informed consent should be obtained from the legal guardian in
accordance with national legislation. Where physical or mental incapacity makes it impossible
to obtain informed consent, or when the subject is a minor, permission from the responsible
relative replaces that of the subject in accordance with national legislation.
The Revised Declaration of Helsinki does not mention research based on presumed
consent. On the other hand, in II. 5 it is stated that if the doctor considers it essential not to
obtain informed consent the specific reasons for this proposal should be stated in the
experimental protocol, for transmission to the independent committee. It looks as if under
certain circumstances research without consent is allowed, maybe even in the case of an
unconscious patient, if the ethics committee approves it and the doctor has specific reasons
not to tell the patient.
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The final version of the European Convention on Human Rights and Biomedicine
addresses the protection of persons not able to consent to research with the following
words:2
A 17.1. Research on a person without the capacity to consent as stipulated in Article 6 may be
undertaken only if all the following conditions are met:
i. The conditions laid down in Article 16, sub-paragraphs (i) to (iv), are fulfilled;
ii. The results of the research have the potential to produce direct benefit to his or her
health;
iii. Research of comparable effectiveness can not be carried out on individuals capable
of giving consent;
iv. The necessary authorisation provided for under Article 6 has been given
specifically and in writing; and
v. The person concerned does not object.
2. Exceptionally, under protective conditions prescribed by law, where the research has not
the potential to produce results of direct benefit to the health of the person concerned, such
research may be authorised subject to the conditions laid down in paragraph 1, sub-
paragraphs (i), (iii), (iv) and (v) above, and to the following additional conditions:
i. The research has the aim of contributing, through significant improvement in the
scientific understanding of the individual's condition, disease or disorder, to the
ultimate attainment of results capable of conferring benefit to the person concerned
or to other persons in the same age category or afflicted with the same disease or
disorder or having the same condition.
ii. The research entails only minimal risk and minimal burden for the individual
concerned.
The European Convention on Human Rights and Biomedicine allows in another way
medical experimentation on persons not able to consent. The approach of the Convention is
an abstract and a general one: there is no distinction between the three main groups of
persons not able to consent to research, ie children, incompetent (especially old) adults, and
the unconscious. On the other hand, Arts 6 and following of the Convention on Human
Rights and Biomedicine distinguishes, under the heading "Consent", between children,
incompetent adults and persons who have a mental disorder and gives rules concerning
2 Convention for the protection of the human rights and dignity of the human being with regard
to the applications of biology and medicine: Convention on Human Rights and Biomedicine by
the Council of Europe, 6 June 1996.
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emergency situations and previously expressed wishes. But that chapter is devoted to
medical treatment and not medical research. Art 16 on the other hand refers generally to Art
6, but does not make use of the distinction. As least as far as purely scientific research is
concerned that does not have the potential to produce results of direct benefit to the health
of the experimental subject, the distinction should be made again. There is a great difference
between research on children on the one hand and research on the unconscious, for instance
as far as the formation and use of a control group is concerned.
III GENERAL PREREQUISITES FOR CLINICAL STUDIES
Clinical studies in general have to meet the following conditions. Even if the distinction
is made between therapeutic and non-therapeutic research on the one hand, and the
formation of a test and a control group or different arms of test groups of a study on the
other, there have to be some basic requirements:
An acceptable medical risk;
Informed consent;
A research protocol that shows the scientific merit of the study;
Inclusion and exclusion criteria;
The number of experimental subjects used;
The duration of the study;
Specific reasons for termination of the study;
The protection of privacy;
Means and restriction of publication;
The positive vote of an IRB or an ethics committee.
Naturally there are specific rules, for instance prohibiting experimentation on prisoners
or other people who are deprived of freedom against their will, experimentation with the
mentally handicapped persons, or children etc. These rules are to be found in different
expressions in all the national and international guidelines, declarations, judgments, laws
and conventions. The following may be mentioned by way of example: the Prussian
directive of 19003; the case of United States v Rose;4 trials of war criminals before the
3 Anweisung an die Vorsteher der Kliniken usw v 29,12.1900, Zentralblatt der gesamten
Unterrichtsverwaltung in PreuBen 1901, 188 f.
4 United States v Rose as part pro toto of the so-called Medical case.
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Nuremburg Military Tribunals.5 the Declaration of the World Medical Association;6
Recommendations guiding doctors in clinical research, the Convention on Human Rights and
Biomedicine by the Council of Europe;7 the French statute of 1988;8 the German drug law of
19767 and the Good Clinical Practice guidelines of the European Commission.10
All these requirements have to be fulfilled in a clinical study that takes place in the ICU.
Special problems are posed by the informed consent requirement.
IV CONSENT TO CLINICAL STUDIES IN THE ICU
In the intensive care unit there are "normal patients" ie patients with all their faculties
intact. However, they are not willing probands from the outside, rather patients dependent
on the doctor, the nurses and the other personnel in the ICU. From a strict legal point of
view these patients are able to be informed and to give their free consent. The local ethics
committee will naturally ask whether a doctor, who is not taking part in the treatment, is
going to inform the patient and ask for the consent and whether there is any pressure or
friendly persuasion factors that should be absent. Generally speaking experimentation on
these patients is not very different from clinical studies on patients in the hospital generally.
Another typical patient in the ICU is the disabled one. This patient is not able to give
free and timely informed consent. Sometimes these patients are unconscious; others are
handicapped in receiving the information and weighing the pros and cons of giving the
consent because they are, for example, heavily sedated. Here the problem of substituted
consent arises. The following types of substituted consent should be discussed.
Anticipated Consent
The patient is able to give consent before becoming disabled, for instance by anaesthesia.
Two cases show the extent of anticipated consent. In Halushka v University of
Saskatchewanll a student had agreed for $50 to participate in a research project. He had
been told that a new drug would be tried out on him and that a catheter would be used. The
drug turned out to be the general anaesthetic Fluoromar, and the catheter even reached the
5 Trials of War Criminals before the Nuremburg Military Tribunals, Vol 2 (1947),
6 Above nt.
7 Above n2. Convention on Human Rights and Biomedicine, by the Council of Europe, 6 June
1996.
8 Loi No 88 - 1138, 20.12.1988, Gaz Pal, Legislation 1988, 605.
9 Gesetz zur Neuregelung des Arzneimittelrechts, 24.8.1976 BGBI. 1976 I 2445.
10 Good Clinical Practice for Trials on Medical Products in the European Community 1991.
11 Halushka v University of Saskatchewan (1965) WWR 608 (Court of Appeals, Saskatchewan).
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heart. During this stage, for a short time, the heart stopped beating, but it was restored to its
function again. The court allowed the anticipated consent, in scientific experimentation, but
the student won the case. The information had been incomplete and his consent was
therefore invalid.
In the case of Karp v Cooly12 the patient had agreed to receive an artificial heart that
was still in the experimental stage. During an operation it became necessary to install the
experimental device. The patient died two days later having received a heart transplant in
between. In this case the court held that the patient was able, after full information, to agree
to the therapeutic experimentation that could have saved his life.
Consent by Proxy
In treatment it has become accepted practice that another person, especially the spouse
or a near relative, is given the power of attorney in health care. In a German case of 199013
the patient had stipulated that according to the findings of the neurosurgeons, his wife
should make the decision whether to perform a certain extirpation or not. The operating
team forgot to ask the wife of the patient and went on. Because of the mixed result of the
surgery the patient sued and won the case. The same measure of informed consent by an
empowered relative could be used in medical experimentation, at least if it is of therapeutic
value.
Consent by Guardian
The legal representative of a child or a mentally handicapped adult is able to consent to
experimental medical measures. Some statutes give the parents this right in a limited way, eg
the German drug statute § 40 Abs. 4 AMG and the French statute of 1988. In the California
case of Nielsen u Regents of the University of California,14 a former member of the IRB sued
the university to abstain from a purely scientific experimentation on children. Healthy
children were to be compared with children whose parents had already developed allergic
reactions. All kinds of tests were envisaged, especially the taking of blood and injections
under the skin like a puncture. The parents were to be paid $300 for the participation of
their children in the clinical trial. The court allowed the trial because it did not seem cruel
for the children to participate.
12 Karp v Cooly 493 F2s 408 (1974) (Court of Appeals).
13 LG GOttingen VersR 1990, 1401.
14 Nielsen v Regents of the University of Cal(fornia, Superior Court of California, 8 December 1975.
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Presumed Consent
Consent should be given in writing, orally, or at least, for example by participation,
implied. Intensive care, especially on unconscious victims of traffic accidents, works on the
principle of presumed consent. The presumption being that the patient would allow all
medical interventions in the patient's favour, unless otherwise stipulated. Presumed consent
is sometimes invoked in clinical studies as well. The Hanover Ethics Committee has agreed
to a clinically controlled study on patients with severe burning concerning Beta-Interferon.
While the control group received the normal treatment for severe burning, the patients in the
test group were given Beta-Interferon additionally. Since all patients were unable to give a
valid consent this was done under the presumption of consenting to promising medical
measures. Participation in the trial did not cause any danger to the control group, however
those patients did not receive the new treatment.
Deferred Consent
The ratification of a measure in a clinical study, that has been performed on the patient
already, could be termed deferred consent. It is probably based on the assumption of
presumed consent also. In the late eighties in Berlin there was a study of elderly patients
who had suffered nearly fatal tachycardiac symptoms. The clinically controlled study
concerned about 300 patients, half of whom got a calcium antagonist and the other half who
were infunded with a placebo. The patients, having become conscious later on, were told
that they had been included in the clinical study and were asked for their belated
permission. If the permission was given, the study at least retrospectively had been
performed with consent. If the permission had been withheld or the patient had died, all the
doctors could do was to fall back on the idea of presumed consent.
Summary
The above discussed examples show that in the cases that reach courts or ethics
committees there was a difference between the single measure intervention as in the Karp u
Cooly and the Halushka cases and the clinically controlled trials as in the Hanover and
Berlin cases. The clinically controlled studies leave the doctor less room to adapt the
medical measures for the purposes of the patient. On the other hand the outcome is
statistically more relevant. The more the discretion of the doctor is removed, and objective
criteria of the research protocol take over, the less there is reason for presumed consent
because patients will rarely contemplate taking part in a clinical study. But on the other
hand they might think of an accident with grave consequences where an unproved method
was indicated. Therefore it is easier to assume they would have consented as far as the
single measure is concerned. To ascertain the opinion of the patient the doctor should ask
near relatives or other people who know the patient well. In questions of clinical studies
for the benefit of the patients in the test group usually the idea of necessity comes into play.
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If the patient were not enrolled in the study, the chance of becoming better would be missed.
The presumed consent might be based on this ground.
The other difference is that of the purely scientific experimentation as against the study
that might directly be of benefit to the health of the patient. A purely scientific enterprise
was the basis of the case of Halushka v University of Saskatchewan. The trying out of a
totally new general anaesthetic on a proband was of purely scientific nature. But the
proband gave his anticipated consent. A case of medical experimentation for the direct
benefit of the patient can be found in Karp v Cooly. Here the use of an artificial heart was
the last step in a desperate fight to save a person. The patient had already consented and
under these circumstances what the doctors did was unusual but justified.
If one may draw a conclusion from the international and national rules, the researcher
has to exclude purely scientific research with no possible direct benefit to the patient in
cases where presumed consent or deferred consent are indicated. Even in a controlled
clinical study where the control group just gets the standard treatment one could still argue,
although with less justification, that participating in the study somehow enhanced the
chances of the patient for recovery.
V RESEARCH ON BRAIN DEAD PERSONS
The discussion whether brain dead persons are dead or dying does not concern this
article. If experimentation on brain dead persons happens in the ICU it will rarely be done
as a clinical study. The Ghttingen Ethics Committee a few years ago had such a proposal.
The research protocol was drafted with the idea of testing all kinds of reflexes of brain-
dead persons awaiting explantations of at least one of their organs. Since the patients'
relatives had not been informed or asked for their permission and because of other reasons
the Ethics Committee did not grant approval.
The recent Milhaud case in the Conseil d'ttat in France15 concerned a single experiment
orl a brain-dead person. Here a forensic physician was called upon to testify in a murder
trial. His expert testimony was to answer the question whether someone could have been
killed with a certain mixture of different gases. To prove his point the doctor administered
that mixture to a person declared brain dead. The relatives of the patient had not been
asked. The ethics committee had not been consulted. The case went up to the highest French
administrative court where the principle that brain-dead persons are really dead was
approved. Nevertheless, the court required the doctor to get the permission of the ethics
committee and to ask the near relatives whether that experimentation could be performed.
15 Lebreton "Le droit, le medicine et la mort" Recueil Dalloz-Sirey 1994 Chronique 352.
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VI ICU STUDIES AND ETHICAL COMMITTEES
ICU studies are not the normal fare of ethical committees, in fact some members of ethics
committees are a bit apprehensive about going over a protocol from the ICU. They know
that all kinds of problems will arise: the doctor/patient relationship, less competent or
totally incompetent patients, the question whether a control group is necessary, the
difference between therapeutical and purely scientific studies.
Normally on an effective ethics committee there are sitting members who are familiar
with the routine in ICU's or running ICUs themselves. It is absolutely necessary for an
ethics committee to have a clear picture of what is going on in an ICU, and whether a
clinical study can be performed there under the circumstances. In this respect the number of
available patients/probands is important; sometimes it is doubtful whether there will be
enough participating patients to give a meaningful statistical answer. The ethics committee
should be local. This committee alone should judge whether the facilities of the hospital are
sufficient for such a study. Permission or positive advice by so-called "international",
"European" or "independent free" ethics committees are not helpful in this respect. They will
not be able to judge the local conditions. This applies even to multi-centre studies where
different ICUs are part of the deliberation of the ethics committee. That the ethics committee
is involved in such studies reveals the Revised Declaration of Helsinki II.5. There it is
stated that the doctor may consider it essential not to obtain informed consent. In this case a
specific reason should be stated in the protocol for transmission to the independent
committee. The independent committee is the local ethics committee and the circumstances
under which the doctor thinks it necessary not to obtain the informed consent can be
therapeutical privilege or a presumed, maybe even deferred, consent.
Rule II.5 of the Revised Declaration of Helsinki lets the ethics committee act as a kind of
substitute for the person. The ethics committee in doing this should insist that the a doctor
involves the next of kin of the patient in the process of decision-making. The relatives or
persons with whom the patient has been living are used to find out what the response
would have been if the patient had been faced with the question. The presumed consent has
to be tailored to the individual patient. The relatives cannot give the consent themselves
unless appointed guardian. At least under continental European law, they are simply
persons who can tell the doctor about the positions, beliefs and statements the patient has
made or held earlier. The ethics committee has to make certain that best endeavours are
made to find out and follow the patient's wishes.
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VII LIABILITY AND COMPENSATION
In nearly all countries in the world there is liability for medical negligence if it has not
been especially abolished by law, as in New Zealand.16 But even there punitive damages
can be asked for.17 Court cases because of negligent experimentation go back to 1767.18
Liability for clinical trials that were not consented to has been upheld in recent times again
and again in the United States,19 as well as in the Federal Republic of Germany.20
Negligence not only provides for material damages, but includes payment because of pain
and suffering. Negligence implies that the standard of care has not been adhered to, but this
is hard to prove. Because medical experimentation (especially clinical studies) ask the
participant to make a personal sacrifice for the good of humankind, there are many
instances where compensation or some kind of third party insurance, or even an objective
liability, is provided.
The French law of 1988 gives an example of an objective liability:21
16 Palmer Compensation for Incapacity (Oxford, 1979); Giesen International Medical Malpractice Law
(1988) No. 1098 ff; Deutsch Kunstfehler und medizinischer Behandlungsunfall in Neuseeland VersR
1980,201.
17 Green v Matheson [1989] 3 NZLR 564 (Court of Appeal).
18 Slater v Baker and Stapelton (1767) 95 ER 1860.
19 United States v Stanley 107 S Ct 3054 (1987); Fiorentino v Wenger 227 NE 2d 296 (New York Court of
Appeals, 1967); Valenti v Prudden 397 NYS 2d 181 (1977).
2 0 BGHZ 20, 61 (1956); OLG Stuttgart VersR 1981, 342.
21 Loi No. 88-1138 20.12.88 i.d F des Loi No 90-86 23.1.90
Art. L. 209-7. - Pour les recherches biomedicales sans ban@fice individuel direct, le promoteur
assume, m@me sans faute, l'indemnisation des consequences dommageables de la recherche pour
la personne qui s'y prete, sans que puisse @tre oppose le fait d'un tiers ou le retrait volontaire de la
personne qui avait initialement consenti A se pr@ter A la recherce.
Pour les recherches biomedicales avec bdnefice individuel direct, le promoteur assume
l'indemnisation des consdquences dommageables de la recherche pour la personne qui s'y prete,
sauf preuve A sa charge que le dommage n'est pas imputable A sa faute ou A celle de tout
intervenant, sans que puissent @tre oppos@ le fait d'un tiers ou le retrait volontaire de la personne
qui avait initialement consenti A se pr@ter A la recherche.
Pour toute recherche biomedicale, le promoteur souscrit une assurance garantissant sa
responsabilit6 civile telle qu'elle resulte du prdsent article et celle de tout intervenant
independamment de la nature des liens existant entre les intervenants et le promoteur. Les
dispositions du present article sont d'ordre public. (Gaz Pal, Legislation 198, 605; J.O. 25.1.90).
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Art. L. 209-7
In the case of biomedical research which has no direct individual benefit, the promoter
undertakes, even iii the absence of fault, to provide compensation for all the consequences of
the research which cause loss for the person who participates in it, and that liability is not
affected by the act of a third party or the voluntary withdrawal from the research of a person
who had initially agreed to it.
In respect of biomedical research which has direct individual benefit, the promoter of the
research assumes liability to compensate the person who participates in the research for any
loss suffered as a consequence of that research, unless the promoter proves that the loss is not
a result of its fault or of any other person involved, but the liability is not excluded by the act
of a third person or the voluntary withdrawal from the research programme of a person who
initially consented to participate.
In the case of all biomedical research, the promoter must take out insurance which guarantees
compensation for any civil liability which may result under the present article or which may
result from any other participant regardless of the nature of the relationship which might
exist between those other persons and the promoter. The provisions of this article are a
matter of public policy.
The French law has regulated all biomedical research, but the German Pharmaceutical
Act of 1976 deals only with testing pharmaceuticals. In Germany the experimental subject
will be granted relief by a third party accident insurance even if nobody is liable for the
experimental accident:22
22 40 Abs. 1
Allgemeine Voraussetzungen
(1) Die klinische Prafung eines Arzneimittels darf bei Menschen nur durchgefuhrt werden,
wenn und solange
1. die Risiken, die mit ihr fur die Person verbunden sind, bei der sie durchgefuhrt werden
soll, gemessen an der voraussichtlichen Bedeutung des Arzneimittels fur die Heilkunde
arztlich vertretbar sind;
2. die Person, bei der sie durchgefuhrt werden soll, ihre Einwilligung hierzu erteilt hat,
nachdem sie durch einen Arzt uber Wesen, Bedeutung und Tragweite der klinischen
Prufung aufgeklart worden ist, und mit dieser Einwilligung zugleich erklart, dass sie mit der
im Rahmen der klinischen Prufung erfolgenden Aufzeichnung von Krankheitsdaten und
ihrer Weitergabe zur Oberprufung an den Auftraggeber, an die zustandige
Oberwachungsbeharde oder die zustundige Bundesoberbehorde einverstanden ist;
3. die Person, bei der sie durchgefuhrt werden soll, nicht auf gerichtliche oder behodliche
Anordnung in einer Anstalt untergebracht ist;
4. sie von einem Arzt geleitet wird, der mindestens eine zweijahrige Erfahrung in der
klinischen Prufung von Arzneimitteln nachweisen kann;
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7th Section - Protection of the Human Being during the Clinical Trial
S40- General preconditions
(1) The clinical trial of a drug shall only be performed on human beings if and as long as
1. the risks, which are involved, for the person with whom the trial is to be carried out, are
medically justifiable, when compared with the anticipated significance of the drug for
medical science;
2. the person, with whom the clinical trial is to be carried out, has given his consent,
having been informed by a physician of the nature, significance and scope of the clinical
trial;
3. the person with whom the trial is to be carried out, is not confined by order of neither
judicial nor administrative authorities;
4. it is run under the supervision of a physician, who can prove to have gained at least
two years experience in the field of the clinical trial of drugs;
5. an appropriate pharmacological-toxicological test has been carried out complying with
the respective prevailing level of scientific findings;
5. eine dem jeweiligen Stand der wissenschaftlichen Erkenntnisse entsprechende
pharmakologisch-toxikologische Prafung durchgefuhrt worden ist;
6. die Unterlagen aber die pharmakologisch-toxikologische Prufung, der dem jeweiligen Stand
der wissenschaftlichen Erkenntnisse entsprechende Prufplan mit Angabe von Prafern und
Pruforten und die Voten der Ethik-Kommissionen bei der zustandigen Bundesoberbeharde
vorgelegt worden sind;
7. der Leiter der klinischen Prafung durch einen fur die pharmakologisch-toxikologische
Prufun verantwortlichen Wissenschaftler Ober die Ergebnisse der pharmakologisch-
toxikologischen Prufung und die voraussichtlich mit der klinischen Profung verbundenen
Risiken informiert worden ist und;
8. far den Fall, dass bei der Durchfuhrung der klinischen Prikfung ein Mensch getotet oder
der Korper oder die Gesundheit eines Menschen verletzt wird, eine Versicherung nach
Massgabe des Absatzes 3 besteht, die auch Leistungen gewahrt, wenn kein anderer fur den
Schaden haftet.
(2)
(3) Die Versicherung nach Absatz 1 Nr. 8 muss zugunsten der von der klinischen Prefung
betroffenen Person bei einem im Geltungsbereich dieses Gestezes zum Geschaftsbetrieb
zugelassenen Versicherer genommen werden. Ihr Umfang muss in einem angemessenen
Verhaltnis zu den mit der klinischen Prufung verbundenen Risiken stehen und fur den Fall des
Todes oder der dauernden Erwerbsunfahigkeit mindestens eine Million Deutsche Mark betragen.
Soweit aus der Versicherung geleistet wird, erlischt ein Anspruch auf Schadensersatz.
(4) „
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6. the documents on the pharmacological-toxicological test are deposited with the
competent federal higher authority;
7. the person directing the clinical trial has been informed by a scientist responsible for the
pharmacological-toxicological test about the findings of said test and the risks to be
anticipated with the clinical trial.;
7a. a test plan according to the present level of scientific findings is available and
8. should a person be killed or the body or the health of a person be hurt iii the course of
the clinical trial, an insurance as specified in para 3 exists which guarantees benefits even
if no other party is liable.
(2) A consent as specified in para 1 sub-para 2 shall only be effective if the person giving it
1. has legal capacity and is in the position to comprehend the nature, significance and
scope of the clinical trial and to determine his decision accordingly'
2. has given the consent in person and has given it in writing.
The consent may be revoked at any time.
(3) The insurance specified in para 1 sub-para 8 must be taken out in favour of the person
undergoing the clinical trial with an insurer authorised to carry out business within the
purview of this law. The scope of the insurance must be in an adequate proportion to the
risks involved in the clinical trial and in the case of death or permanent disability must total at
least five hundred thousand Deutschmarks. As far as benefits are paid by the insurance, any
claim for damages shall be extinguished.
(4) In respect of a clinical trial carried out with minors, paras 1 to 3 shall apply with the
following conditions:
1. The drugs must be intended to diagnose or prevent diseases in minors.
2. The administration of the drug must be considered necessary pursuant to the findings
of medical science to diagnose or prevent diseases in the minor.
3. Adequate test results pursuant to the findings of medical science are not to be
anticipated from the clinical trial carried out with adults.
4. The consent shall be given by the legal representative or guardian. It shall only be
effective if this person has been informed by a physician of the nature, significance and
scope of the clinical trial. If the minor is in the position to comprehend the nature,
significance and scope of the clinical trial and to determine his decision accordingly, then
his written consent shall also be required.
In other countries guidelines issued by associations of the pharmaceutical industry are
helpful. In Great Britain the Association of the British Pharmaceutical Industry obliges its
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members to provide compensation on an objective basis for patients taking part in a clinical
trial. As in Germany the British self-rule applies just to drug testing, not to other biomedical
research as in France. There have been some problems in Great Britain with
pharmaceutical companies that sponsor drug trials shouldering their responsibility. Some
ethics committees have now put specific questions to the companies and only after a
satisfactory statement is obtained ethical approval will be given.23
VIII CONCLUSION
Up to now it looks like the French and the German statutory provisions are most
satisfactory, if one disregards the limitation on drug trials in Germany. Whether the
liability for presumed fault in cases of therapeutic experimentation or the strict liability for
purely scientific experimentation is better than a third party accident insurance should only
be answered after some time and the opportunity to compare the outcome of both systems.
Because of the special circumstances of clinical research in ICUs there should be an
insurance coverage that does not apply just in cases of negligence, but that applies on an
objective basis either as liability insurance for strict liability or as accident insurance
directly granted to the experimental subject.
23 Barton, McMillan and Sawyer "The Compensation for Patients Injured in Clinical Trials" Journal
of Medical Ethics 1995 (21) 166 et seq. Cf. Milne "Compensation for Adverse Consequences of
Medical Intervention" in Goldberg ed Pharmaceutical Medicine and the Law (1991) 111.
